Lyell Immunopharma, Inc.
LYEL$498M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSOUTH SAN FRANCISCO300 employees
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
LYEL News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
rondecabtagene autoleucel | Phase 3 | Large B-cell Lymphoma | - | - |
LYL314 | Phase 2 | Relapsed Non-Hodgkin Lymphoma | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply